In 2016, Cives et al. reported that MGMT status by IHC failed to predict the response to CAPTEM in 143 pancreatic NET patients; MGMT status by IHC was not prognostic either [19]. This evidence concerns the gene MGMT and pancreatic neuroendocrine tumor.